Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections

References

• EdelsbergJTanejaCZervosMTrends in US hospital admissions for skin and soft tissue infectionsEmerg Infect Dis20091591516151819788830
   PubMed Web of Science ®Google Scholar
• JarvisWRJarvisAAChinnRYNational prevalence of methicillin-resistant Staphylococcus aureus in inpatients at United States health care facilities, 2010Am J Infect Control201240319420022440670
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionActive Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin-Resistant Staphylococcus aureus2012
   Google Scholar
• RayGTSuayaJABaxterRIncidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based studyBMC Infect Dis20131325223721377
   PubMed Web of Science ®Google Scholar
• LodiseTPFangEMinassianSLProkocimerPPlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH Clinical TrialsAntimicrob Agents Chemother201458127198720425246392
   PubMed Web of Science ®Google Scholar
• ShawKJPoppeSSchaadtRIn vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strainsAntimicrob Agents Chemother200852124442444718838596
   PubMed Web of Science ®Google Scholar
• ChenHYangQZhangRIn vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multi-centre study in ChinaInt J Antimicrob Agents201444327627725108879
   PubMed Web of Science ®Google Scholar
• ProkocimerPBienPDeandaCPillarCMBartizalKIn vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infectionsAntimicrob Agents Chemother20125694608461322687509
   PubMed Web of Science ®Google Scholar
• Rodriguez-AvialICulebrasEBetriuCMoralesGPenaIPicazoJJIn vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococciJ Antimicrob Chemother201267116716921954458
   PubMed Web of Science ®Google Scholar
• SahmDFDeaneJBienPAResults of the surveillance of tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and EuropeDiagn Microbiol Infect Dis201581211211825488274
   PubMed Web of Science ®Google Scholar
• SchaadtRSweeneyDShinabargerDZurenkoGIn vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agentAntimicrob Agents Chemother20095383236323919528279
   PubMed Web of Science ®Google Scholar
• ThomsonKSGoeringRVActivity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological originsAntimicrob Agents Chemother20135762892289523571550
   PubMed Web of Science ®Google Scholar
• LockeJBZurenkoGEShawKJBartizalKTedizolid for the management of human infections: in vitro characteristicsClin Infect Dis201458Suppl 1S35S4224343830
   PubMed Web of Science ®Google Scholar
• FlanaganSDBienPAMunozKAMinassianSLProkocimerPGPharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugPharmacotherapy201434324025023926058
   PubMed Web of Science ®Google Scholar
• SahreMSabarinathSGrantMSkin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersInt J Antimicrob Agents2012401515422584101
   PubMed Web of Science ®Google Scholar
• Sivextro™ lyophilized powder for intravenous injection, oral tablets, tedizolid phosphate lyophilized powder for intravenous injection, oral tablets [Product information]Cubist PharmaceuticalsLexington, MA2014
   Google Scholar
• FlanaganSMinassianSLMorrisDPharmacokinetics of tedi-zolid in subjects with renal or hepatic impairmentAntimicrob Agents Chemother201458116471647625136024
   PubMed Web of Science ®Google Scholar
• FlanaganSPassarellJLuQFiedler-KellyJLudwigEProkocimerPTedizolid population pharmacokinetics, exposure response, and target attainmentAntimicrob Agents Chemother201458116462647025136028
   PubMed Web of Science ®Google Scholar
• FlanaganSMinassianSLPassarellJFiedler-KellyJProkocimerPTedizolid plasma pharmacokinetics are comparable in obese and non-obese patients and healthy subjectsPaper presented at: 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)May 10–13, 2014Barcelona, Spain
   Google Scholar
• Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults Available from: https://www.clinicaltrials.gov/ct2/show/NCT2342418?term=tedizolid&rank=3Accessed January 30, 2015
   Google Scholar
• LouieALiuWKulawyRDrusanoGLIn vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection modelAntimicrob Agents Chemother20115573453346021502615
   PubMed Web of Science ®Google Scholar
• DrusanoGLLiuWKulawyRLouieAImpact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection modelAntimicrob Agents Chemother201155115300530521911576
   PubMed Web of Science ®Google Scholar
• KeelRATessierPRCrandonJLNicolauDPComparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection modelAntimicrob Agents Chemother20125684403440722687504
   PubMed Web of Science ®Google Scholar
• ProkocimerPBienPSurberJPhase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infectionsAntimicrob Agents Chemother201155258359221115795
   PubMed Web of Science ®Google Scholar
• ProkocimerPDe AndaCFangEMehraPDasATedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trialJAMA2013309655956923403680
   PubMed Web of Science ®Google Scholar
• MoranGJFangECoreyGRDasAFDe AndaCProkocimerPTedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialLancet Infect Dis201414869670524909499
   PubMed Web of Science ®Google Scholar
• FlanaganSBartizalKMinassianSLFangEProkocimerPIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactionsAntimicrob Agents Chemother20135773060306623612197
   PubMed Web of Science ®Google Scholar
• FlanaganSMcKeeEEDasDNonclinical and pharmacoki-netic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionAntimicrob Agents Chemother201559117818525331703
   PubMed Web of Science ®Google Scholar
• PatelNVanDeWallHTristaniLA comparative evaluation of adverse platelet outcomes among Veterans’ Affairs patients receiving linezolid or vancomycinJ Antimicrob Chemother201267372773522174041
   PubMed Web of Science ®Google Scholar
• AthanasakisKPetrakisIOllandezosMAntibacterial treatment of meticillin-resistant staphylococcus aureus complicated skin and soft tissue infections: a cost and budget impact analysis in Greek hospitalsInfect Dis Ther201432257268
   PubMedGoogle Scholar
• BarronJTurnerRJaegerMAdamsonWSingerJComparing the use of intravenous antibiotics under the medical benefit with the use of oral antibiotics under the pharmacy benefit in treating skin and soft tissue infectionsManag Care2012219445223050424
   PubMedGoogle Scholar
• MenzinJMartonJPMeyersJLCarsonRTRothermelCDFriedmanMInpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureusAm J Infect Control2010381444919762120
   PubMed Web of Science ®Google Scholar
• SchurmannDSorensenSVDe CockEDuttaguptaSReschACost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in GermanyEur J Health Econ2009101657918437437
   PubMed Web of Science ®Google Scholar
• De CockESorensenSLevratFCost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in FranceMed Mal Infect200939533034019304423
   PubMed Web of Science ®Google Scholar
• McCollumMSorensenSVLiuLZA comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patientsClin Ther200729346947717577468
   PubMed Web of Science ®Google Scholar
• SharpeJNShivelyEHPolkHCJrClinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureusAm J Surg2005189442542815820454
   PubMed Web of Science ®Google Scholar
• RosnerAJBeckerDLWongAHMillerEConlyJMThe costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in CanadaCan J Infect Dis Med Microbiol200415421322018159495
   PubMedGoogle Scholar